BioNTech SE's (BNTX) stock soared 5.01% in the pre-market trading session on Thursday, February 13, 2025. The rally was fueled by reports denying the involvement of the Wuhan Institute of Virology in the creation or leakage of the COVID-19 virus that led to the global pandemic.
China's Foreign Ministry spokesperson, Guo Jiakun, reiterated that the Wuhan Institute of Virology played no role in the design, production, or release of the SARS-CoV-2 virus that caused the COVID-19 pandemic. This statement comes after reports emerged about the U.S. Agency for International Development (USAID) funding gain-of-function studies at the institute, which could have triggered the worldwide outbreak.
The denial from Chinese authorities has bolstered confidence in BioNTech, one of the leading developers of COVID-19 vaccines. BioNTech's partnership with Pfizer produced the Comirnaty vaccine, which has been widely used globally in the fight against the pandemic. The positive news has alleviated concerns about potential liabilities related to the vaccine's development and distribution, driving the stock's surge.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。